Hi Cure,

We’re looking forward to gathering with the FAST community at the Science Summit & Gala in December.

Today, we’re excited to share new updates about the agenda. Enjoy!

If you have updates you would like to be included in next week’s newsletter, please email us at info@cureangelman.org.

FAST has been busy in 2022 and we are excited to share our accomplishments with you! 

In 45 days, the community will unite in Florida for the 2022 FAST Global Science Summit & Gala. We are pleased to announce that the detailed schedule of events is now available! We have an exciting lineup of speakers to inform the community about FAST’s many advancements toward a cure for Angelman syndrome. The Science and Pharma Summit agenda is focused on educating the community about the groundbreaking research being undertaken to bring transformative treatments to every individual living with Angelman syndrome. This will include an introduction to novel therapeutic platforms being developed for Angelman syndrome, updates on ongoing clinical trials and those that we will hopefully be starting in the near term, and news about initiatives in place to help support clinical trial readiness and design. Be ready for your questions to be answered live by our renowned researchers and pharmaceutical participants!

After all that good learning, we look forward to coming together as a community at the Gala, where we will laugh, share, dance, and raise vital funds to keep all of this progress moving.

Click here for the FAST Science Summit and Gala schedule of events:

Key dates:

10/31/22 - Deadline to book the nightly group rate at The Diplomat

11/18/22 - Deadline to purchase in-person tickets

FAST is excited to grant the New Investigator Award to Dr. Michael Sidorov, from Children’s Research Institute at the Children’s National Hospital, and Dr. Abigail Dickinson from UCLA at the Center for Autism Research and Treatment. 

We are pleased to have Dr. Dickinson join the Angelman syndrome community!

This New Investigator Award will support the evaluation of peak alpha frequency as a potential Electroencephalogram (EEG) biomarker for individuals living with Angelman syndrome, for potential use in clinical trials.

“Receiving a new investigator grant from FAST allows my lab to develop Angelman EEG biomarkers for clinical trials. Developing new biomarkers is so important in order to give current and future trials the best possible chance of succeeding. It was a hard few years starting my new lab during the pandemic, and this FAST award makes such a difference in jumpstarting our work.”

- Dr. Sidorov

“It's an exciting time for clinical trials in AS, and I feel very fortunate to work with Dr. Sidorov on novel biomarkers that could help target and track intervention in individuals with AS.”

- Dr. Dickinson

Click here to read more:

Topic: Facilitating Access to Future Treatments

Date: 11/01/22 at 4pm CST (Chicago) / 5pm EST (New York)

Guest: FAST Board Member, Lauren Hoffer

FAST is preparing for the future when drugs for AS may become available, and we’ve started working hard to help ensure the environment for access is favorable for the community. We are excited to have Lauren join us to break it all down for the community. 

Click here to register:

Read more about what FAST is doing to help make sure the AS community will be able to access a drug once it’s approved:

We hope to see you in Hollywood, Florida this December! 🌴 As always, we’d appreciate it if you could share this link with anyone who would be interested in receiving our updates.